3 Cutting-Edge Biotech Stocks Sitting on the Brink of Success
In the ever-growing world of biotechnology discovery, three stocks have lots of room to grow in 2024 Biotech stocks have always been high-risk and high-reward, with the futures and fortunes of companies often decided with a single successful drug trial or Federal Drug Administration (FDA)…#biotech #fda #huntington #bntx #pfizer #covid19vaccine #yoy #exelixisinc #cabometyx #eps (Source: Reuters: Health)
Source: Reuters: Health - March 6, 2024 Category: Consumer Health News Source Type: news
FDA approves inotuzumab ozogamicin for pediatric patients with acute lymphoblastic leukemia
On March 6, 2024, the Food and Drug Administration approved inotuzumab ozogamicin (Besponsa, Pfizer) for pediatric patients 1 year and older with relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - March 6, 2024 Category: Drugs & Pharmacology Authors: FDA Source Type: news
FDA Approves Besponsa (inotuzumab ozogamicin) for Pediatric Patients with Acute Lymphoblastic Leukemia
On March 6, 2024, the Food and Drug Administration approved inotuzumab ozogamicin (Besponsa, Pfizer) for pediatric patients 1 year and older with relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia (ALL).
Efficacy was... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - March 6, 2024 Category: Drugs & Pharmacology Source Type: news
Hot on the Hedge Funds ’ Trail: 3 Stocks Worth Your Bet?
Invest in these hedge fund stocks for a standout Q4 performance The fourth quarter (Q4) shined bright for hedge funds, marking it a standout period in the investment realm. According to a recent report released by a U.K.-based data investment business, global hedge fund returns surged 7.1% in Q4,…#q4 #q3 #pharma #pfizer #fda #seagen #pfe #yoy #att #moderatebuy (Source: Reuters: Health)
Source: Reuters: Health - March 2, 2024 Category: Consumer Health News Source Type: news
Pfizer, looking for a jumpstart, leans into cancer drug research
Pfizer believes the answer to its sliding valuation lies in oncology. The company, which is coming off one of the worst years in its history, unveiled on Thursday a new business unit dedicated to cancer research. The division, created in the wake of Pfizer’s $43 billion buyout of Seagen last year,…#pfizer #seagen #leerinkpartners #davidrisinger #ibrance #elilillys #novartis #adcetris #padcev #phase3 (Source: Reuters: Health)
Source: Reuters: Health - March 2, 2024 Category: Consumer Health News Source Type: news
Pfizer shutting down Seagen's $350M construction project in Everett
In December, Pfizer completed its $43 billion acquisition of Bothell-based Seagen, which was building the manufacturing site. (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - March 2, 2024 Category: Biotechnology Authors: Neetish Basnet Source Type: news
RSV Vaccine May Be Linked to a Slightly Higher Risk of Guillain-Barre Syndrome
NEW YORK — Health officials are investigating whether there’s a link between two new RSV vaccines and cases of a rare nervous system disorder in older U.S. adults.
The inquiry is based on fewer than two dozen cases seen among more than 9.5 million vaccine recipients, health officials said Thursday. And the available information is too limited to establish whether the shots caused the illnesses, they added.
[time-brightcove not-tgx=”true”]
But the numbers are higher than expected and officials are gathering more information to determine if the vaccines are causing the problem. The data was pre...
Source: TIME: Health - March 2, 2024 Category: Consumer Health News Authors: Mike Stobbe/AP Tags: Uncategorized healthscienceclimate wire Source Type: news
Puzzling skin side effects stymie advance of promising HIV vaccine
One of the most promising attempts to reinvigorate the stalled quest for an HIV vaccine has hit a snag that might seem minor but has major consequences: delaying the larger trials needed to show whether the concept works. In small safety and immune tests of the innovative vaccine strategy, which relies on a series of messenger RNA (mRNA) shots, an unusually high percentage of recipients developed rashes, welts, or other skin irritations.
“We are taking this very seriously,” says Carl Dieffenbach, who heads the Division of AIDS at the National Institute of Allergy and Infectious Diseases, which funded a recent pha...
Source: ScienceNOW - March 1, 2024 Category: Science Source Type: news
Pfizer Says Its RSV Shot Is Protective Through a Second Year Pfizer Says Its RSV Shot Is Protective Through a Second Year
Pfizer on Thursday said a single dose of its new respiratory syncytial virus (RSV) vaccine Abrysvo maintained its ability to protect against the illness through a second...Reuters Health Information (Source: Medscape Infectious Diseases Headlines)
Source: Medscape Infectious Diseases Headlines - February 29, 2024 Category: Infectious Diseases Tags: Infectious Diseases Source Type: news
Pfizer announces positive top-line data for full season two efficacy of ABRYSVO ® for RSV in older adults
Pfizer Inc. (NYSE: PFE) today announced top-line ABRYSVO® vaccine efficacy and safety data for respiratory syncytial virus (RSV) in adults 60 years of age and older following a second season in the Northern and Southern Hemispheres from the ongoing pivotal Phase 3 clinical trial (NCT05035212) RENOIR (RSV vaccine Efficacy study iNOlder adults Immunized against RSV disease). (Source: World Pharma News)
Source: World Pharma News - February 29, 2024 Category: Pharmaceuticals Tags: Featured Pfizer Business and Industry Source Type: news
Health chiefs 'failed to sound alarm over potential dangers of Covid vaccines': MPs accuse regulator of putting Brits 'at serious risk' by not immediately sharing how Pfizer jabs could trigger extremely rare heart side effect
A cross-party group of politicians have called for an urgent investigation into the medicines regulator after uncovering evidence it knew about Covid jab side effects months before issuing warnings. (Source: the Mail online | Health)
Source: the Mail online | Health - February 28, 2024 Category: Consumer Health News Source Type: news
Study Finds Increasing Time Between COVID Vaccine Doses Reduces Risk Of Myocarditis, Yet Cardiologists Raise Concerns
Authored by Megan Redshaw via The Epoch Times (emphasis ours), New research suggests increasing the interval between vaccine doses or using a single dose may significantly lower…#meganredshaw #epochtimes #npjvaccines #hongkong #pfizer #cardiologist #kirkmilhoan #clevelandclinic #departmentofhealth #cdc (Source: Reuters: Health)
Source: Reuters: Health - February 27, 2024 Category: Consumer Health News Source Type: news
Why is €2 billion worth of COVID drug Paxlovid going to waste?
European countries rushed to buy the antiviral drug in January 2022, but now it’s going to waste. Why? A COVID-19 antiviral drug has been underused in Europe with about 3.1 million courses of the medicine set to expire in the UK, Germany, Spain, Italy, and France by the end of this month. With…#spain #airfinity #pfizer #marcogallotta #lifescienceanalyst #euronewshealth #gallota #pbs #askojärvinen #hus (Source: Reuters: Health)
Source: Reuters: Health - February 25, 2024 Category: Consumer Health News Source Type: news
The Shot That Will Be Heard Round The Halls Of Congress
Authored by Gerrick Wilkins via RealClear Wire, Upwards of 80% of Americans favor term limits, yet entrenched politicians in Congress – and the lobbyists who need them to advance their special interests – have found ways of quashing them time…#gerrickwilkins #realclearwire #unshacklingdemocracy #garypalmer #usconstitution #pfizer #pac #obamacare #realclearpublishing (Source: Reuters: Health)
Source: Reuters: Health - February 25, 2024 Category: Consumer Health News Source Type: news
Pfizer Stock Has 29% Upside, Says a New Bull
(Source: Reuters: Health)
Source: Reuters: Health - February 23, 2024 Category: Consumer Health News Source Type: news
